FDA-AACR Regulatory Science and Policy Workshop
FDA-AACR Workshop to Examine Under-representation of African Americans in Multiple Myeloma Clinical Trials
Date: 8 a.m. - 5 p.m. Feb. 13, 2020
Location: Washington Marriott at Wardman Park, 2660 Woodley Rd. NW, Washington, D.C. 20008
Register for in-person or webcast participation. See the draft agenda.
- Discuss biology and genetics underlying racial and ethnic differences in multiple myeloma.
- Characterize racial and ethnic data available from multiple myeloma registrational trials and real-world data sources.
- Discuss implications of limited clinical data in racial and ethnic minorities with multiple myeloma.
- Explore approaches to increase our knowledge of the safety and efficacy of anti-myeloma therapeutics in racial and ethnic minorities.
Kenneth C. Anderson, MD, FAACR, program director, Jerome Lipper Multiple Myeloma Center and LeBow Institute for Myeloma Therapeutics and chief, Division of Hematologic Neoplasia, Dana-Farber Cancer Institute; chair, AACR Regulatory Science and Policy Subcommittee
Lola A. Fashoyin-Aje, MD, MPH, acting deputy director, Division of Oncology 3, Office of Oncologic Diseases, Center for Drug Evaluation and Research, U.S. Food and Drug Administration
Nicole J. Gormley, MD, acting director, Division of Hematologic Malignancies 1, Office of Oncologic Diseases, Center for Drug Evaluation and Research, U.S. Food and Drug Administration
Paul G. Kluetz, MD, deputy director, Oncology Center of Excellence, U.S. Food and Drug Administration